Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Show more
Location: 301 Binney Street, Cambridge, MA, 02142, United States | Website: https://generationbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
25.9M
52 Wk Range
$0.30 - $3.65
Previous Close
$0.39
Open
$0.40
Volume
1,998,393
Day Range
$0.39 - $0.45
Enterprise Value
-48.52M
Cash
157.6M
Avg Qtr Burn
-21.31M
Insider Ownership
14.37%
Institutional Own.
72.37%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|